Synergistic interaction of antibiotics with nasal penetration to methicillin-sensitive and methicillin-resistant <i>Staphylococcus aureus</i>

Chow, Joseph W.; Hilf, Megan; Yu, Victor L.

doi:10.1093/jac/27.4.558

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rifampin-fusidic acid combination appears to demonstrate synergy rather than indifference by several in vitro studies (82,86,254). The rifampin-novobiocin combination demonstrates synergy or indifference by in vitro studies, especially when there are heavy inocula of bacteria (48,135,258). Most of the in vitro data were reported many years ago, before standards were established for all laboratories, but the results are not discouraging.…”

Section: Staphylococcimentioning

confidence: 99%

Rifampin Combination Therapy for Nonmycobacterial Infections

2010

View full text Add to dashboard Cite

SUMMARY The increasing emergence of antimicrobial-resistant organisms, especially methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy. The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clinical studies. Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations. A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed. The clinical data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-negative staphylococci. Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clinically or experimentally. Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections. Lastly, an assessment of the risk-benefits is needed before the addition of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities.

show abstract

Section: Staphylococcimentioning

confidence: 99%

Rifampin Combination Therapy for Nonmycobacterial Infections

2010

View full text Add to dashboard Cite

show abstract

“…Both drugs are well absorbed, with a long half-life and good tissue penetration and they act synergistically in vitro against MRSA. 7 , 8 Data from pre-clinical pharmacodynamic models also support the likely efficacy of the combination against tetracycline and rifampicin sensitive MRSA strains. 9 Two single-arm studies have been performed which have showed promising efficacy of tetracyclines for cSSSIs by MRSA.…”

Section: Introductionmentioning

confidence: 93%

Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: the AIDA open label, randomized, controlled Phase 4 trial

et al. 2023

View full text Add to dashboard Cite

Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections

Perlroth

Kuo²,

Tan³

et al. 2008

Arch Intern Med

202

129

View full text Add to dashboard Cite

Background: Staphylococcus aureus causes severe lifethreatening infections and has become increasingly common, particularly methicillin-resistant strains. Rifampin is often used as adjunctive therapy to treat S aureus infections, but there have been no systematic investigations examining the usefulness of such an approach. Methods: A systematic review of the literature to identify in vitro, animal, and human investigations that compared single antibiotics alone and in combination with rifampin therapy against S aureus.Results: The methods of in vitro studies varied substantially among investigations. The effect of rifampin therapy was often inconsistent, it did not necessarily correlate with in vivo investigations, and findings seemed heavily dependent on the method used. In addition, the quality of data reporting in these investigations was often suboptimal. Animal studies tended to show a microbiologic ben-efit of adjunctive rifampin use, particularly in osteomyelitis and infected foreign body infection models; however, many studies failed to show a benefit of adjunctive therapy. Few human studies have addressed the role of adjunctive rifampin therapy. Adjunctive therapy seems most promising for the treatment of osteomyelitis and prosthetic device-related infections, although studies were typically underpowered and benefits were not always seen. Conclusions:In vitro results of interactions between rifampin and other antibiotics are method dependent and often do not correlate with in vivo findings. Adjunctive rifampin use seems promising in the treatment of clinical hardware infections or osteomyelitis, but more definitive data are lacking. Given the increasing incidence of S aureus infections, further adequately powered investigations are needed.

show abstract

Synergistic interaction of antibiotics with nasal penetration to methicillin-sensitive and methicillin-resistant Staphylococcus aureus

Cited by 6 publications

References 0 publications

Rifampin Combination Therapy for Nonmycobacterial Infections

Rifampin Combination Therapy for Nonmycobacterial Infections

Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: the AIDA open label, randomized, controlled Phase 4 trial

Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections

Contact Info

Product

Resources

About